Focus on AJOVY injection: A new Anti- CGRP Treatment For Migraine Prevention

FOCUS ON AJOVY™ (fremanezumab-vfrm) injection: A NEW ANTI-CGRPTREATMENT

FOR MIGRAINE PREVENTION

OVERVIEW

During this program, there will be a presentation on and discussion of AJOVY™(fremanezumab-vfrm)

injection for the preventive treatment of migraine, including the efficacy and safety of AJOVY based on its Prescribing Information. Additionally,

there will be discussion of how to begin treatment with AJOVY.

OBJECTIVES

•

AJOVY, a new anti-CGRP treatment for migraine prevention

AJOVY efficacy and safety in clinical trials

Starting on AJOVY

•

•

Teva is required to disclose all items of value provided to healthcare providers and to disclose these amounts publicly. By attending this speaker program, you are accepting the disclosure of the cost of the meal.

INDICATION

AJOVY™ is indicated for the preventive treatment of migraine in adults.

IMPORTANT SAFETY INFORMATION

Contraindications: AJOVY is contraindicated in patients with serious hypersensitivity to fremanezumab-vfrm or to any of the excipients.

Hypersensitivity Reactions: Hypersensitivity reactions, including rash, pruritus, drug hypersensitivity, and urticaria were reported with AJOVY in clinical trials. Most reactions were mild to moderate, but some led to discontinuation or required corticosteroid treatment. Most reactions were reported from within hours to one month after administration. If a hypersensitivity reaction occurs, consider discontinuing AJOVY and institute appropriate therapy.

Adverse Reactions: The most common adverse reactions (≥5% and greater than placebo) were injection site reactions.

Please see the full Prescribing Information for AJOVY.

RSVP TO

Alan Ayars

alan.ayars@tevapharm.com

(682) 559-2386

DATE

JAN 24th, 2019

LOCATION

Ruth Chris Steak House

813 Main St.

Fort Worth, TX

FACULTY MODERATOR

Joseph Casaly, MD

Medical Director

Headache Center of North Texas